» Articles » PMID: 20142589

Whole-genome Profiling of Pediatric Diffuse Intrinsic Pontine Gliomas Highlights Platelet-derived Growth Factor Receptor Alpha and Poly (ADP-ribose) Polymerase As Potential Therapeutic Targets

Overview
Journal J Clin Oncol
Specialty Oncology
Date 2010 Feb 10
PMID 20142589
Citations 182
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Diffuse intrinsic pontine glioma (DIPG) is one of the most devastating of pediatric malignancies and one for which no effective therapy exists. A major contributor to the failure of therapeutic trials is the assumption that biologic properties of brainstem tumors in children are identical to cerebral high-grade gliomas of adults. A better understanding of the biology of DIPG itself is needed in order to develop agents targeted more specifically to these children's disease. Herein, we address this lack of knowledge by performing the first high-resolution single nucleotide polymorphism (SNP) -based DNA microarray analysis of a series of DIPGs.

Patients And Methods: Eleven samples (nine postmortem and two pretreatment surgical samples), the largest series thus far examined, were hybridized to SNP arrays (250 k or 6.0). The study was approved by the research ethics board at our institution. All array findings were validated using quantitative polymerase chain reaction, fluorescence in situ hybridization, immunohistochemistry, and/or microsatellite analysis.

Results: Analysis of DIPG copy number alterations showed recurrent changes distinct from those of pediatric supratentorial high-grade astrocytomas. Thirty-six percent of DIPGs had gains in platelet-derived growth factor receptor alpha (PDGFRA; 4 to 18 copies) and all showed PDGFR-alpha expression. Low-level gains in poly (ADP-ribose) polymerase (PARP) -1 were identified in three cases. Pathway analysis revealed genes with loss of heterozygosity were enriched for DNA repair pathways.

Conclusion: To our knowledge, our data provides the first, comprehensive high-resolution genomic analysis of pediatric DIPG. Our findings of recurrent involvement of the PDGFR pathway as well as defects in DNA repair pathways coupled with gain of PARP-1 highlight two potential, biologically based, therapeutic targets directed specifically at this devastating disease.

Citing Articles

An innovative cellular medicine approach via the utilization of novel nanotechnology-based biomechatronic platforms as a label-free biomarker for early melanoma diagnosis.

Alqabandi J, David R, Abdel-Motal U, ElAbd R, Youcef-Toumi K Sci Rep. 2024; 14(1):30107.

PMID: 39627312 PMC: 11615046. DOI: 10.1038/s41598-024-79154-z.


Emerging roles of cancer-associated histone mutations in genomic instabilities.

Yadav P, Jain R, Yadav R Front Cell Dev Biol. 2024; 12:1455572.

PMID: 39439908 PMC: 11494296. DOI: 10.3389/fcell.2024.1455572.


Dual targeting of histone deacetylases and MYC as potential treatment strategy for H3-K27M pediatric gliomas.

Algranati D, Oren R, Dassa B, Fellus-Alyagor L, Plotnikov A, Barr H Elife. 2024; 13.

PMID: 39093942 PMC: 11296706. DOI: 10.7554/eLife.96257.


CAR-T cells for H3K27-altered diffuse midline gliomas: where do we stand?.

Power E, Millesi E, Rechberger J, Daniels D Immunotherapy. 2024; 16(12):775-778.

PMID: 39016046 PMC: 11457631. DOI: 10.1080/1750743X.2024.2373043.


Contemporary Management of Pediatric Brainstem Tumors.

Chou S, Chen Y, Huang H, Kuo M, Wong T, Kuo S Adv Tech Stand Neurosurg. 2024; 49:231-254.

PMID: 38700687 DOI: 10.1007/978-3-031-42398-7_11.